Fish Oil (DHA, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), EPA (fish oils), fish oils, marine oils, menhaden oil, N3 fatty acids, omega 3 PUFA, polyunsaturated fatty acids, PUFA, W3 fatty acids, shark liver oil)
Classes: Cardiovascular, Herbals; Neurology & Psychiatry, Herbals
Suggested dosing of DHA, docosahexaenoic acid (DHA) (fish oil)
Bipolar Disorder, Adjunct Treatment
6.2 g EPA/3.4 g DHA PO daily
Cyclosporine Nephrotoxicity
12 g PO daily
Dysmenorrhea
1080 mg EPA/720 mg DHA PO daily
Hypercholesterolemia
4 g PO daily
Hypertension
4 g PO daily
Hypertriglyceridemia
1-4 g PO daily
See also Omacor
Post CABG
4 g PO daily
Post MI
0.85-1.08 g EPA PO daily
Raynaud's Syndrome
3.96 g EPA/2.64 g DHA PO daily
Rheumatoid Arthritis
3.8 g EPA/2 g DHA PO daily
Sclerosing Cholangitis (Orphan)
Orphan designation for docosahexaenoic acid (DHA) to treat primary sclerosing cholangitis
Sponsor
- Sancilio and Company, Inc.; 3874 Fiscal Ct, Suite 100; Riviera Beach, FL 33404
Familial Adenomatous Polyposis (Orphan)
Treatment of familial adenomatous polyposis
Orphan indication sponsor
- S.L.A. Pharma Ltd. (UK); Elite House Leavesden, Watford WD25 7SA; UK
Huntington's Disease (Orphan)
Treatment of familial adenomatous polyposis
Orphan indication sponsor
- Laxdale Ltd; Kings Park House, Laurelhill Business Park, Polmaise Road, Stirling FK7 9JQ; UK
IgA Nephropathy (Orphan)
Orphan indication sponsor
- Pronova Biocare, AS; PO Box 420, 1327 Lysaker; Norway
Sickle Cell Disease (Orphan)
Docosahexaenoic acid (DHA)
Orphan designation for treatment of sickle cell disease
Sponsor
- Sancilio and Company, Inc; 3874 Fiscal Ct., #100; Riviera Beach, FL 33404
Short Bowel Disease (Orphan)
Docosahexaenoic acid (DHA)
Orphan designation for treatment of short bowel disease
Sponsor
- Sancilio and Company, Inc; 3874 Fiscal Ct., #100; Riviera Beach, FL 33404
Suggested uses of DHA, docosahexaenoic acid (DHA) (fish oil)
Bipolar disorder, coronary heart disease, dysmenorrhea, hyperlipidemia, HTN, hypertriglyceridemia, Raynaud's syndrome, rheumatoid arthritis, stroke prevention
Decr risk of prostate CA (dietary fish)
Rheumatoid arthritis, psoriasis, other chronic inflammatory conditions
DHA, docosahexaenoic acid (DHA) (fish oil) adverse (side) effects
Frequency not defined
Bleeding
Halitosis
Heartburn
Hemorrhagic stroke
Immunosuppression
Increased LDL cholesteroL
Nausea
Weight gain
Warnings
Contraindications
Diabetes, immunodeficiency
Cautions
Aspirin sensitivity, bipolar disorder, bleeding disorders, cirrhosis, concurrent antihypertensives, familial adenomatous polyposis, major depressive disorders
Pregnancy and lactation
Pregnancy category: N/A
Lactation: N/A
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of DHA, docosahexaenoic acid (DHA) (fish oil)
Metabolism: N/A
Excretion: N/A
Mechanism of action
Inhibits platelet aggregation; decr production of inflammatory prostaglandins (e.g., PGE2)
Inhibits oxidation of LDL, inhibits migration of macrophages into atherosclerotic plaques